Evidence map›Paper›PMID 30287781›Full record

ReviewPharmaceuticals (Basel, Switzerland)2018

Sucrosomial

Susana Gómez-Ramírez, Elisa Brilli, Germano Tarantino, Manuel Muñoz

3 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05678647 nacompletednot on this mapstarted 2023, after this paper: background citation

Randomized Open Comparative Trial of Oral Sucrosomial Iron (SiderAl Forte®) and Oral Iron Sulphate (Duroferon®) to Blood Donors.

TypeinterventionalSponsorUppsala University HospitalRan2023 to 2026Enrolled120ConditionsBlood DonationArmsSucrosomial Iron, Iron Sulfate
NCT06521879 nacompletednot on this mapstarted 2022, after this paper: background citation

Improved Gastrointestinal Tolerance and Iron Status Via Probiotic Use in Iron Deficiency Anemia Patients Initiating Oral Iron Replacement

TypeinterventionalSponsorAntalya Training and Research HospitalRan2022 to 2023Enrolled295ConditionsIron Deficiency Anemia Treatment, Iron Deficiency AnemiaArmsLactobacillus plantarum 299v probiotic support
NCT07483645 active not recruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness and Acceptability of a Liposomal Iron Supplement With Vitamin C and Fiber (LISEFEX®): Observational, Descriptive, Prospective, Longitudinal, Multicenter Study in Mexican Subjects Diagnosed With Mild to Moderate Iron Deficiency Anemia.

TypeobservationalSponsorCarnot LaboratoriesRan2025 to 2026Enrolled74ConditionsIron Deficiency Anemia
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. A review - Prescribing iron salts: Comparison of efficacy and tolerance of different iron complexes.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2026
    Review
  12. Article
  13. Patient blood management in pregnancy, the peripartum, and the postpartum period.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026
    Article
  14. Article
  15. Article
  16. Iron Deficiency in Heart Failure: Cellular Mechanisms and Therapeutic Implications.Journal of cardiovascular development and disease · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Susana Gómez-RamírezDepartment of Internal Medicine, University Hospital Virgen de la Victoria. Campus de Teatinos, 2010 Málaga, Spain. susanagram@yahoo.es.
Elisa BrilliScientific Department, Alesco S.r.l. Via delle Lenze, 216/B, 56122 Pisa, Italy. elisa.brilli@alescosrl.com.
Germano TarantinoScientific Department, Pharmanutra S.p.A. Via delle Lenze, 216/B, 56122 Pisa, Italy. g.tarantino@pharmanutra.it.
Manuel MuñozPerioperative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, Campus de Teatinos, 29071 Málaga, Spain. mmunoz@uma.es.ORCID 0000-0002-2052-8959
Hospital Clínico Universitario Virgen de la Victoria · ESUniversidad de Málaga · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency (ID) is usually treated with oral iron salts, but up to 50% of patients complain of gastrointestinal side effects, leading to reduced treatment compliance. Intravenous (IV) iron formulations are increasingly safer, but there is still a risk of infusion and hypersensitivity reactions and the need for a venous access and infusion monitoring. Sucrosomial

Indexed as

anemiabioavailabilityefficacyintravenous ironiron deficiencyM cellsoral iron saltsSucrosomial® irontolerability

Identifiers

PMID30287781
PMCPMC6316120
OpenAlexW2895639972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.